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Quantitative chemical proteomics identifies novel targets of the anti-cancer multi-kinase inhibitor E-3810
Colzani et al. Supplementary Figure S10 . Fragmentation spectra for putative E3810 interactors from the competition assay that were identified with 2 peptides, of which 1 unique (LYN and CSPB (1)).
SUPPLEMENTARY FIGURE LEGENDS
Supplementary Figure S11 . Fragmentation spectra for putative E3810 interactors from the K d assay that were identified with 2 peptides, of which 1 unique (FGFR2, ACTBL2 and DPDE3).
Supplemental Table S1 . Half-maximal inhibitory concentration (IC 50 ) obtained by in vitro kinase assay for both non-derivatized and derivatized E-3810 (corresponding to compound 1 and 4 in Figure S1 ). Compounds were tested against the kinases FGFR-1, -2, -3 and VEGFR-1 and -2, already characterized as targets of E-3810. c-kit and VEGFR-3 were included as negative controls.
E-3810 derivatization leads to a slight increase of IC 50 values, which was considered acceptable for the chemoproteomics screening.
Supplementary Table S2 . Unsupervised clustering of putative targets. Putative E-3810 targets selected by SILAC competition assay were grouped in 3 clusters based on the trends of ratio modulation from sample A to D. The three clusters, automatically generated by GproX, group the proteins in the following categories: proteins eluted at low (cluster 1, high affinity), intermediate (cluster 2, medium affinity) and high concentrations (cluster 3, low affinity) of E-3810. For each protein, the number of the cluster is indicated for both the forward and reverse experiments.
